Illumina price targets raised to $210 by Leerink, $190 by Canaccord

0 min read | Published on 14 Jul 2026, 06:33 PM |Updated on 17 Jul 2026, 11:48 PM

Reviewed by

Radhika SScanX News Team

Key Highlights

Leerink Partners analyst Puneet Souda maintained an Outperform rating on Illumina, raising the price target to $210 from $175. Canaccord Genuity analyst Kyle Mikson kept a Hold rating while increasing the price target to $190 from $140.

*this image is generated using AI for illustrative purposes only.

Leerink Partners analyst Puneet Souda has maintained an Outperform rating on Illumina and raised the price target to $210 from $175. Separately, Canaccord Genuity analyst Kyle Mikson maintained a Hold rating and increased the price target to $190 from $140. These adjustments signal revised valuation outlooks for the company's shares.

Rating and Price Targets

Leerink Partners retained its positive stance, indicating potential upside based on the updated financial model. Canaccord Genuity kept a neutral view, suggesting a balanced risk-reward profile at the new price level.

Firm	Analyst	Rating	Previous Price Target	New Price Target
Leerink Partners	Puneet Souda	Outperform	$175	$210
Canaccord Genuity	Kyle Mikson	Hold	$140	$190

Illumina is listed on the NASDAQ under the ticker symbol ILMN.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific factors drove Leerink Partners to raise the price target significantly more than Canaccord Genuity?

How might Illumina's upcoming product launches influence the divergence in analyst ratings?

What are the key risks that could prevent Illumina from reaching the new price targets?

Evercore ISI raises Illumina target to $200

0 min read | Published on 26 Jun 2026, 07:38 PM |Updated on 07 Jul 2026, 12:43 AM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

Evercore ISI Group analyst Vijay Kumar maintained an Outperform rating on Illumina and raised the price target to $200 from $155, reflecting confidence in the genomics firm's growth. This move aligns with similar bullish sentiment from Piper Sandler and Guggenheim, both of which also have a $200 price target, while Bernstein holds a Market Perform rating at $185.

*this image is generated using AI for illustrative purposes only.

Evercore ISI Group analyst Vijay Kumar has maintained an Outperform rating on Illumina (NASDAQ: ILMN) and raised the price target to $200 from $155. The adjustment signals increased confidence in the genomics company's valuation and growth trajectory.

Illumina specializes in providing tools and systems for genetic analysis within the genomics sector. The new price target of $200 offers investors a revised benchmark for assessing the stock's potential upside against current trading levels.

This update follows a separate rating action by Piper Sandler analyst David Westenberg, who maintained an Overweight rating with a price target of $200. Additionally, Guggenheim analyst Subbu Nambi has a Buy rating with a price target of $200, while Bernstein analyst Eve Burstein assigned a Market Perform rating with a price target of $185.

Firm	Analyst	Rating	Price Target
Evercore ISI Group	Vijay Kumar	Outperform	$200
Piper Sandler	David Westenberg	Overweight	$200
Guggenheim	Subbu Nambi	Buy	$200
Bernstein	Eve Burstein	Market Perform	$185